|Description||Tanzisertib, also known as CC-930, is a potent, selective, and orally active JNK inhibitor with potential antifibrotic activity. CC-930 entered Phase I clinical trials. Tanzisertib may have potential use for prevention and treatment of dermal fibrosis. Selective inhibition of JNK by CC-930 exerted potent antifibrotic effects in vitro and in different models in vivo. JNK might thus be a novel molecular target for the treatment of fibrosis in SSc.|
|B0084-462798||25 mg||$198||In stock|
|Synonyms||CC-930; CC 930; CC930|
|Current Developer||Celgene Corporation|
JIP-1 (153-163) has been found to be a peptide inhibitor of c-Jun N-terminal kinase (JNK), based on residues 153-163 of JNK-interacting protein-1 (JIP-1).
CC 401 dihydrochloride is a potent JNK inhibitor (Ki = 25-50 nM). CC 401 competitively binds to ATP-binding site of phosphorylated JNK to inhibit JNK.
JNK-IN-8 inhibits c-Jun phosphorylation in HeLa and A375 cells with EC50 of 486 nM and 338 nM, respectively.
BI 78D3 is a competitive c-Jun N-terminal kinase (JNK) inhibitor (IC50 = 280 nM) with > 100 fold selectivity over p38α and no effect on mTOR and PI-3K. BI 78D3 ...
CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity. The activation of...
AS601245 is a JNK Inhibitor with IC50s of 150, 220, and 70 nM for three JNK human isoforms (hJNK1, hJNK2, and hJNK3), respectively.
JNK Inhibitor IX
JNK inhibitor IX is a selective and potent JNK inhibitor with pIC50 of 6.5 and 6.7 for JNK2 and JNK3, respectively.
ATP-competitive, selective JNK inhibitor. Decreases c-Jun transcription activity and proliferation. Decreases cytochrome c release and caspase 3 activation. Sho...
IQ-1S free acid
IQ-1S free acid is a potent, selective c-Jun N-Terminal Kinase inhibitor with a preference for JNK3 (IC50=390, 360 and 87 nM for JNK1, 2 and 3 respectively). In...
Tanzisertib, also known as CC-930, is a potent, selective, and orally active JNK inhibitor with potential antifibrotic activity. CC-930 entered Phase I clinica...
AS 602801 is a novel, orally active inhibitor of JNK. It blocked T-lymphocyte proliferation and induced apoptosis.
AEG 3482 has been found to be an inhibitor of c-jun N-terminal kinase (JNK) signaling and could probably be useful against some neurological disorders.
IQ 1S is a c-Jun N-terminal kinase (JNK) inhibitor. It inhibits the production of nitric oxide in vitro and inhibits the release of nitric oxide upon metabolism...
Covalent modification of IRAK1 by JNK-IN-7 is a possibility and subsequent biochemical kinase assay revealed anIC50 of ~10 nM against IRAK1. JNK-IN-7 exhibited ...
SU 3327 is a selective inhibitor of c-Jun N-terminal kinase (JNK) (IC50 = 0.7 μM) with selectivity over p38 MAPK and Akt. SU 3327 inhibits the interaction betwe...
IQ 3 is a selective and specific c-Jun N-terminal kinase 3 (JNK3) inhibitor with Kd value of 66 nM. It inhibits TNF-α and IL-6 production in vitro and inhibits ...
DB07268 is a potent and selective JNK1 inhibitor. It has some degree of selectivity over quite a few kinases with the exceptions of CHK1, CK2, and PLK.
SP-600125 is a specific JNK inhibitor. SP600125 kills p53-deficient cells more efficiently than their p53-proficient counterparts, in vitro. Similar observation...
SR-3306, an aminopyrimidine derivative, is a JNK Inhibitor and could be mainly active in Phosphorylation & Dephosphorylation actions.
SR 3576 is a potent and selective JNK3 inhibitor (IC50 = 7 nM) with > 2800-fold selectivity over p38.